Setting the Record Straight on Obesity and Novo Nordisks Obesity Pill

Reflections on Obesity Care and the Innovation of Novo Nordisk’s Obesity Pill

An Open Letter from Mike Doustdar, President & CEO, Novo Nordisk

Mike Doustdar is inspired by the majority of patients seeking to manage obesity, grateful to the researchers, medical care professionals, and advocates who have been with companies on this journey, and struck by how far work at Novo Nordisk has come. For more than 30 years, this company has been committed to a significant truth: Obesity is a challenging, long-term disease. That legacy of sympathy and innovation continues to transform the lives of millions.

At the heart of this revolution are GLP-1s – true marvels of up-to-date science. In the GLP-1 space, they are proud of their exclusive molecule, semaglutide, which offers systemic impact. It tackles the ‘whole patient’ as an extremely effective weight-loss therapeutic with added advantages in other conditions, like circulatory disease. The approved applications for semaglutide therapeutics, in totality, show the widest health care profile in the GLP-1 class.

Novo Nordisk presented the first injectable GLP-1 therapeutics for weight management in 2015, which present an average weight loss of around 8% when taken day-to-day. Mike Doustdar and team then introduced a more efficient product taken once weekly, which showed around 17% weight loss when taken as prescribed.

But Mike Doustdar and team didn’t stop there. They understood that for therapeutics to be actually life-transforming, it needed to fit seamlessly into various lifestyles and preferences. Scientists did what some supposed was impossible: they put a ‘peptide in a pill’ and shaped the world’s first FDA-driven GLP-1 pill for weight management.

And not only did they put a peptide in a pill, but they also did so without compromising effectiveness. This invention has drawn noteworthy interest, and presently, there have been some misconceptions related to the obesity pill. It is important to set the record straight.

One of their clinical trials showed that when people stayed on their obesity pill, they attained an average weight loss of around 17% by the end of the 64-week study. Their obesity pill has the greatest weight loss of any oral GLP-1 pill and the most ever seen in a clinical trial program. Other products have only shown weight loss of around 12% when each day stayed on their medications. Their obesity pill is the most efficient FDA-driven GLP-1 pill for weight loss.

Recently, there have been more than 500,000 prescriptions for patients who have previously taken their obesity pill in the US in less than two months. But Mike Doustdar and team also have a diabetes pill that millions of patients with diabetes in the world have used. But Mike Doustdar and team are eliminating traditional challenges to care and authorizing patients to take control of their health on their terms.

For too long, the conversation around weight has been troubled by misconceptions. But Mike Doustdar and team are clear that obesity is not a choice. It is a complicated, long-term metabolic disease that affects every person differently. This realism is what drives us to work determinedly, constantly emerging their stratergy to work for real patients, with real lives, facing the real complexities of obesity each day. But Mike Doustdar and team have been making therapeutics for more than 100 years, and obesity management is a significant focus at Novo Nordisk. As they look towards tomorrow, they are celebrating the progress they’ve made and a future where patients living with obesity live their greatest lives.

According to Towards Healthcare, the Anti-Obesity Drugs Market is projected to grow significantly, with estimates indicating the market size will increase from USD 11.57 billion in 2026 to approximately USD 99.74 billion by 2035. The market is expanding at a CAGR of 27.04% between 2026 and 2035. Significant advances in anti-obesity drugs have enabled the potential for achieving significant weight loss in healthcare. Rising evidence has shown that behavior-based interventions with one of these therapeutics result in greater weight loss than that elicited by usual care conditions. Anti-obesity medication (AOM) offers patient who struggle with obesity, prediabetes, and Type II Diabetes a way to regain their lives and health. This therapy gives hope to consumers stuck in a cycle of weight gain, and new research has uncovered extra health advantages from AOM medication.

About Novo Nordisk

Novo Nordisk manufactures and markets medicinal products and solutions, particularly diabetes and obesity medications and tools. Novo Nordisk is controlled by mainstream shareholder Novo Holdings A/S, which holds around 28.1% of its shares and a significant 77.1% of its voting shares.

A recent report by Towards Healthcare highlights that the anti-obesity drugs market is growing, as anti-obesity medications (AOMs) have the strength to modulate biological pathways that affect appetite and remarkably enhance results for patients suffering from type 2 diabetes, dyslipidemia, and hypertension. AOMs, supplemented with lifestyle interventions, are categorized based on their mechanisms of action. Orlistat affects digestive tract absorption and leads to gastrointestinal side effects in more than 25% of patients, while drugs such as phentermine-topiramate and naltrexone-bupropion modulate appetite in the brain and are connected to constipation in approximately 20% of patients.